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I. INTRODUCTION
The primary aim of treatment planning for radical radiotherapy has traditionally been to deliver a uniform high dose to a tumor in order to eradicate all the tumor cells. This aim is formalized in guidance on radiotherapy planning from the International Commission on Radiation Units and Measurements 1,2 and is supported both by years of clinical experience and by mathematical modeling of the radiobiology of tumors. 3 This approach assumes tumors to be uniform, homogeneous entities, a perfectly sensible approximation in the absence of reliable techniques for determining the precise location and the anatomical and functional structure of the tumor, and for calculating and delivering complex dose distributions. However, emerging medical imaging techniques are giving us more information than ever before on structural, biological, and chemical variations within tumors. [4] [5] [6] [7] [8] At the same time, intensity-modulated radiotherapy ͑IMRT͒ techniques give us unprecedented control over the spatial deposition of dose within a patient. 9, 10 There has therefore been much recent discussion regarding how best to incorporate information on tumor inhomogeneities into the treatment planning process in order to produce a genuinely optimal nonuniform dose distribution. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Most approaches to this problem begin with a mathematical model describing the response of the tumor to irradiation, and propose using imaging techniques to estimate spatial variations in the key parameters of this model ͑usually tumor burden and radiosensitivity͒. However, the values used are often baseline values of radiosensitivity parameters that come from in vitro studies, [22] [23] [24] [25] or at best clinical studies giving a population average. [26] [27] [28] There are therefore large uncertainties in the values of these parameters for a given individual patient, causing errors in estimating the absolute effect of varying dose distributions. However, with the development of novel imaging agents and improvements in quantitative functional imaging, it may soon be possible to quantify tumor response by imaging before and after an initial course of treatment. 8, 29 Patient-specific radiobiological parameters could then be derived from this assessment and used to plan a further course of treatment. The aim of this work is not to develop quantitative functional imaging techniques themselves, but rather to investigate and develop strategies for using the information that is expected to come from these techniques. We present methods both for deriving patient-specific radiobiological parameters and for designing optimal dose distributions based on those parameters.
II. METHODS

II.A. Patient-specific optimization
We begin with a multiparameter model describing the response of a tumor to treatment. In order to accurately predict the response of a particular tumor to a given course of treatment, we must have accurate knowledge of the value of each significant parameter. Some parameters, notably those relating to tumor burden and chemical environment, may be assessed by acquiring appropriate images of the tumor prior to treatment. However, parameters relating to the dynamic response of the tumor cannot be ascertained in this manner and a different approach is needed, the most common being to use the results of in vitro studies or analyses of clinical outcome as an estimate. However, there is evidence that there may be significant variations in radiosensitivity within a population of otherwise similar tumors. 30, 31 In order for a model to produce useful predictions, it may therefore be necessary to determine patient-specific values for these parameters. We consider two approaches to this problem: the first is to acquire images of the tumor before and after a single phase of treatment, and numerically optimize the set of unknown parameters such that the response predicted by the model best matches the observed response; the second is to determine how much information is needed in order to derive the unique set of unknown parameters analytically and to design a sequence of treatment phases and image acquisitions to acquire this information. Here we apply both of these techniques to a specific radiobiological model and assess the feasibility, accuracy, and robustness of each.
II.B. Radiobiological model
We follow the approach of Webb and Nahum 32 by considering a tumor divided into n equal-sized voxels, each of volume . If the radiation response is described by the linearquadratic model, the surviving fraction ͑SF͒ of tumor cells following irradiation to dose D in f fractions is given by
where ␣ and ␤ are the linear and quadratic parameters of cell kill, ␥ is the repopulation rate, and ⌬t the overall treatment time. The tumor control probability ͑TCP͒ is found by assuming Poisson statistics and calculating the probability of there being no viable tumor cells remaining. The probability of killing all tumor cells within a single voxel i is given by
where i is the clonogenic cell density in voxel i and D i is the dose delivered to voxel i. The overall TCP for the whole tumor is then the product of the TCPs for all voxels:
͑3͒
In order to choose the dose distribution ͑i.e., the set of D i values for a chosen f and ⌬t͒ which will give the best overall TCP ͑subject to any dose delivery constraints͒, we need to know the spatial distribution of , ␣, ␤, and ␥. At this point we will assume that the linear and quadratic parameters have some intrinsic value for a given patient, which is then modulated by spatial variations in chemical or biological properties within the tumor. The dominant modulating factor is likely to be oxygenation, since hypoxia is known to dramatically reduce radiosensitivity. [33] [34] [35] We therefore require both a means of determining the intrinsic values of ␣, ␤, and ␥, and techniques for quantitatively imaging the distribution of clonogenic cell density and of hypoxia. Recent advances in positron emission tomography and magnetic resonance imaging and spectroscopy, particularly the development of new techniques for imaging tumor cell metabolism 36, 37 and hypoxia, [38] [39] [40] [41] show progress toward fulfilling the imaging requirements. Here we present methods for quantifying the intrinsic radiobiological parameters for a specific patient.
II.C. Deriving patient-specific radiobiological parameters from image data
II.C.1. Method I: Numerical optimization
Given images of the clonogen density distribution before a single initial treatment phase, a good estimate of spatial variations in oxygenation during treatment, and knowledge of the delivered dose, an initial estimate of ␣, ␤, and ␥ values can be used to generate a prediction of the posttreatment clonogen map. If a posttreatment clonogen density image is also acquired, the observed and predicted data can be compared and the parameter values iteratively adjusted to minimize the difference.
Within a given voxel i, phase 1 delivers total dose D i ͓1͔ in f ͓1͔ fractions over a total time ⌬t ͓1͔ . The effective linear and quadratic terms of radiosensitivity will be the intrinsic radiosensitivity terms multiplied by factors A i ͓1͔ and B i ͓1͔ , respectively, such that 
͑5͒
A suitable objective function ͑OF͒ for the optimization process would then be given by
where the sum is taken over all tumor voxels. Minimizing the value of this function should give the best estimate of ␣, ␤, and ␥.
II.C.2. Method II: Analytical derivation
If can be imaged directly, we will then require sufficient information to derive analytically the remaining independent parameters, in this case ␣, ␤, and ␥. If clonogen density is imaged before treatment, then again after each of three test phases of treatment, the linear-quadratic equations can be solved analytically to give effective values of ␣, ␤, and ␥ within each tumor voxel. If spatial variations in oxygenation are also imaged for each treatment phase, these can be accounted for so that intrinsic radiosensitivity values can be derived. Figure 1 shows the sequence of imaging sessions and treatment phases required for the analytical derivation of the radiobiological parameters in this case.
From Eq. ͑5͒ it can be shown that if we consider only the first phase of treatment,
Similar equations hold for phase 2 and phase 3, giving us the following set of relationships between ␣, ␤ and ␥, and the surviving clonogen number following each phase:
͑8͒
This set of equations can be solved voxel by voxel, provided the determinant of the 3 ϫ 3 matrix is nonzero. In practice this means that no two treatment phases can have both the same dose per fraction and the same overall time per fraction. Note that if tumor repopulation is known to be negligible, ␥ can be set to zero and a two-phase treatment would then give sufficient information to solve for ␣ and ␤.
II.D. Optimizing the dose distribution
Having derived patient-specific radiobiological parameters, the most recent set of clonogen density and oxygenation images can then be used to optimize the dose distribution for a final phase of treatment. There are a number of possible approaches to the dose optimization problem, here we have used a method to maximize the overall TCP for a fixed integral dose, similar to that used by Yang and Xing. 19 Details of the method are given in the Appendix.
II.E. Tumor model
The technical feasibility of the above described methods is demonstrated by application to a model tumor. The tumor is spherical with a core of bulk disease of uniform clonogen density surrounded by a region of tumor spread in which clonogen density drops exponentially with distance from the core. 44 With a core clonogen density max , core radius R C , and overall tumor radius R T , the clonogen density varies with radius r as shown in the following.
Uniform intrinsic values of ␣, ␤, and ␥ are specified for the whole tumor. The oxygen dependence takes the form suggested by Wouters and Brown, 42 such that
where p i is the partial pressure of oxygen in voxel i, OER ␣ max and OER ␤ max are maximum oxygen enhancement ratios for ␣ and ␤, respectively, and K m is the oxygen partial pressure at which half-maximum sensitization occurs. The partial pressure of oxygen takes a uniform value p max outside the core, and drops exponentially to a minimum value p min at the center of the core:
The resulting radial profiles for clonogen density and partial pressure of oxygen are shown in Fig. 2 . Maximum and minimum oxygen pressures can be chosen independently for each imaging session and where temporal variations in oxygenation occur, it is assumed that the average of the pre-and posttreatment hypoxia images for each phase represents a good approximation to the effective oxygenation during that treatment phase. For simplicity, the proliferation rate has been chosen to be spatially invariant. However, spatial variations in ␥ as a function of oxygenation could easily be incorporated provided the form of the oxygen dependence was known, although the literature is somewhat inconsistent on this point. 45 
III. RESULTS
III.A. Importance of radiobiological parameters
For spatially varying dose prescriptions to be a viable proposition, the required level of dose inhomogeneity must be both clinically significant and clinically achievable. To investigate the sensitivity of prescribed voxel dose to variations in ␣, ␤, ␥, and , a model tumor with a volume of 100 cm 3 and with a set of literature-derived radiobiological parameters typical of prostate cancer 28 was considered. These parameters are listed in Table I . The voxel dose required to maximize total TCP subject to fixed integral dose was calculated in the case where the reference voxel ͑i.e., a voxel in which all parameters take the reference values͒ receives 78 Gy, with the integral dose equal to that for a uniform irradiation to 78 Gy in 39 fractions. Figure 3 shows the effect on voxel dose of varying each of ␣, ␤, ␥, and over a clinically relevant range, 47 normalized to the reference voxel dose, with all other parameters fixed. It can be seen that the prescribed dose is relatively insensitive to variations in clonogen density, with wide variations in clonogen number resulting in modest alterations in voxel dose. Similarly, prescribed dose does not change dramatically with proliferation rate, except for very rapidly proliferating tumors. However, changes in ␤ and particularly ␣ lead to significant changes in dose within a clinically realistic range. The importance of using patient-specific radiosensitivity can be seen by considering typical quoted values of population variance in ␣ in light of Fig. 3 . Nahum et al. 28 quote a standard error of ␣ = 0.06 Gy −1 for prostate cancers. Variations in ␣ of Ϯ ␣ would correspond to changes of prescribed dose of −13% or +17%, respectively, for this parameter set.
III.B. Method I: Numerical optimization of patientspecific radiobiological parameters
The numerical optimization method was tested by using the above described model tumor to generate observed posttreatment clonogen density images based on an assigned set of radiobiological parameters. Expected clonogen maps based on an initial estimated set of parameters were generated in the same manner. The estimated values were then iteratively optimized to minimize the objective function described in Eq. ͑6͒. However, fundamental limitations of this method quickly became apparent, even when dealing with well-behaved modeled data.
If we consider only a single voxel within the modeled tumor, the objective function ͑OF͒ is given by 
where ␣, ␤, and ␥ are actual values and ␣ est , ␤ est, and ␥ est are estimated values. This function becomes zero when
This condition can be satisfied by numerous combinations of ␣ est , ␤ est , and ␥ est , so in this case the problem is degenerate. Now consider the whole tumor for a case in which phase 1 consists of a uniform irradiation of a tumor with uniform oxygenation. Each voxel contributes a term of the form given in Eq. ͑12͒ to the objective function, with each term simply scaled by the initial clonogen number in that voxel. If the condition in Eq. ͑13͒ is met, then each term will be zero, so the problem remains degenerate. If the phase 1 dose is nonuniform, each voxel has a different value of D ͓1͔ , so Eq. ͑13͒ now represents a set of conditions, each of which must be satisfied in order to find the optimal ␣, ␤, and ␥. This breaks the degeneracy of the problem and results in a single global minimum of the OF, but a large number of local minima remain and the global minimum is extremely narrow, as illustrated in Fig. 4 . The 
3. Sensitivity of the dose prescription for a particular voxel to variations in the value of ͑a͒ effective ␣; ͑b͒ effective ␤; ͑c͒ proliferation rate ␥ ͑potential doubling times of 1, 10, 100, and 1000 days are labeled͒; and ͑d͒ clonogen density . Doses are normalized to a reference voxel with the parameter values given in Table I . optimization process will therefore either be extremely timeconsuming or prone to significant errors, even when considering perfect data. If random noise is introduced into the modeled image data, the depth of the global minimum in the OF is reduced to a much greater extent than that of the local minima. This effect becomes more prominent as the signal-to-noise ratio ͑SNR͒ is reduced and by the time random noise represents just a few percent of the image signal the global minimum is indistinguishable from the local minima. In practice, for any realistic set of clinical images, the problem will once more become effectively degenerate and the optimization process is unlikely to yield reliable, clinically relevant results. We therefore turn our attention to the analytical approach to deriving ␣, ␤, and ␥.
III.C. Method II: Analytical derivation of patientspecific radiobiological parameters
III.C.1. Sensitivity to image noise
When applied to noise-free modeled data in which clonogen density images perfectly represent a tumor for which the linear-quadratic model is an exact fit, this method returns the correct values of ␣, ␤, and ␥ for each voxel. In order to assess the sensitivity of the solutions to image noise, random fluctuations were introduced into the modeled image sets and the errors in calculated parameters assessed. In each case a maximum noise amplitude a N was set as a percentage of voxel signal, and the true voxel value multiplied by a factor 1+ N , where N was randomly selected with uniform probability in the range −a N to +a N for each voxel. Noise was randomly introduced in this way to each of the four clonogen density maps. The tumor model incorporated a standard set of parameter values representative of prostate cancer 28 and a fixed treatment regime for phases 1 to 3 was used, as shown in Table I . The model tumor was fully oxygenated throughout. The noise amplitude was varied between 0% and 100%, the simulation was run ten times for each noise level, and both the mean value and the standard deviation ͑s.d.͒ over the tumor for each parameter ͑␣, ␤, and ␥͒ was recorded on each occasion. Figure 5 shows the RMS of the error in the
value represents the true value of a parameter, whilst the s.d. of the voxel values is representative of the stability of calculation results for individual voxels, given that the tumor model has uniform intrinsic radiosensitivity and proliferation. It is clear that for ␣ and ␤, the mean value is much more stable than the individual voxel values with increasing noise, suggesting that for a realistic SNR it may be necessary to average the radiosensitivity values over the target. For a noise level of 10%, the rms errors of mean values of ␣, ␤, and ␥ are 1.1%, 3.1%, and 9.2%, respectively. When applied to the model outlined in Sec. II E, these errors combine to give an uncertainty in voxel dose of approximately 1%.
III.C.2. Effect of treatment parameters
It should be noted that the sensitivity to noise of the parameter calculation will vary depending on the treatment parameters ͑D, f, and ⌬t͒ chosen for the initial treatment phases. For perfect modeled data, the determinant of the 3 ϫ 3 matrix in Eq. ͑8͒ need only be non-zero. In general, however, increasing the magnitude of the determinant will reduce the effect of noise on the calculation so it would be desirable to maximize the determinant subject to practical or clinical constraints.
To illustrate the effect of the various parameters on the determinant and consequently on the errors in calculated radiosensitivity and proliferation rate, we consider two specific scenarios. First, consider a situation in which phase 1 and phase 2 are both delivered at 2 Gy per fraction. Phase 1 consists of ten fractions delivered over 12 days ͑e.g., daily on weekdays only͒, whilst phase 2 consists of five fractions delivered over 5 days. Supposing we then wish to deliver phase 3 in a single fraction, Fig. 6͑a͒ illustrates the dependence of the determinant upon the size of this fraction. The noise sensitivity analysis described in Sec. III C 1 was repeated using a 10% noise level and standard tumor model as outlined in Table I for a range of determinant values attained by adjusting the phase 3 fraction size, with the results presented in Fig. 6͑b͒ . It can be seen that for large values of the determinant, errors in the mean calculated ␣ and ␤ approach approximately 0.3%, and that errors of both parameters are stable and below 1% when the magnitude of the determinant is greater than 100, corresponding to a phase 3 dose of approximately 3.5 Gy. It should be noted, however, that if D
͓3͔
is fixed then the determinant increases linearly with f ͓3͔ , so a determinant of −100 could equally be achieved if phase 3 consisted of four fractions each of 2.5 Gy. Figure 6͑b͒ also shows that errors in calculated ␥ are unaffected when the determinant is increased in this way, since the overall treatment time is not being changed so the ability to distinguish between different proliferation rates is not improved despite the increase in the determinant.
Second, we consider the effect of varying the overall treatment time for phase 1, with all other parameters fixed. In this case we have chosen phase 3 to consist of three fractions each of 2.5 Gy delivered over 3 days, with all other parameters as in the previous example. The dependence of the determinant on ⌬t ͓1͔ and the consequent errors in computed parameters are shown in Figs. 6͑c͒ and 6͑d͒. In this case it can be seen that increasing the determinant in this way reduces errors in ␣, ␤, and ␥. It is therefore clear that uncertainties in ␣, ␤, and ␥ depend not only on the magnitude of the determinant, but also on the means of increasing the determinant, so the relative importance of errors in these three parameters must be considered when designing the initial treatment phases.
III.D. Optimization of final phase dose distribution
Clonogen density and hypoxia data were generated for five different model tumors ͑without added noise͒, and in each case the radiobiological parameters were derived and the dose distribution giving the maximum TCP was generated. Models Pr1-3 use radiobiological parameters representative of prostate tumors, whilst Br1 and Br2 represent a glioblastoma or high-grade astrocytoma. 23 There is currently some debate in the literature over the choice of radiobiological parameters for modeling prostate cancer, particularly over the ␣ / ␤ ratio 28, [48] [49] [50] [51] [52] [53] [54] . Models Pr1 and Pr2 use the parameters proposed by Nahum et al. 28 with a high ␣ / ␤ ratio, whilst Pr3 uses a parameter set proposed by Wang et al. 52 with a low ␣ / ␤ ratio. Pr1 is well oxygenated, whilst Pr2 has reduced oxygenation in the core throughout the course of treatment. Pr3 is identical to Pr1 except for the choice of ␣, ␤, and values. Br1 contains a core which remains mildly hypoxic throughout treatment, whilst the core of Br2 is initially hypoxic, but is allowed to reoxygenate during the course of treatment. Details of the parameters used for each model are given in Table II , which also includes both the TCP values for uniform irradiation and the maximum achievable TCP for the same integral dose. In each case the correct ␣, ␤, and ␥ values were derived. Figure 7 shows the initial clonogen density and hypoxia maps, and the optimized final phase dose distribution through the center of the tumor for each model.
The results for Pr1 indicate that for a well oxygenated prostate tumor, uniform irradiation gives a high probability of local control and there is relatively little benefit from redistributing dose purely to account for variations in clonogen density. However, when a persistently hypoxic region is introduced in Pr2, the TCP for the conventional treatment drops dramatically, indicating a probable failure of local control, whilst the redistribution of dose allows a TCP close to 1 to be achieved. The maximum final phase voxel dose for Pr2 was 106.2 Gy, representing an increase by a factor of nearly 2.7 compared with the uniform final phase dose of 40 Gy, whilst for Pr1 the maximum voxel dose was 62.7 Gy. Model Pr3 shows that if the ␣ value is lower and the ␤ higher than suggested by Nahum et al. 28 , the TCP for a uniform irradiation is reduced, despite a reduction in clonogen density. However, the redistribution of dose once again allows a TCP in excess of 0.99 to be achieved, with a maximum voxel dose of 59 Gy.
Br1 also suggests that hypoxia can limit the TCP for a conventional treatment, and that redistribution of dose could lead to significant increases in TCP. The maximum voxel dose of 68 Gy represents an increase by a factor of 2.1 compared with the uniform final phase dose of 32 Gy. Br2 highlights the potential importance of imaging hypoxia more than once during the course of treatment. Initially, this tumor appears to have a poorer prognosis than Br1, since it contains more clonogens and has a larger hypoxic region with lower relative oxygenation. However, the hypoxia in this case does not persist through the course of treatment, and consequently the TCP for the conventional uniform dose treatment is higher than for Br1 and the gain in TCP due to redistribution of dose is more modest, as is the increase in maximum voxel dose to 54.9 Gy.
IV. DISCUSSION
We have presented a theoretical framework for optimizing radiotherapy based on patient-specific radiobiological parameters derived from a series of functional images. This method has been illustrated by application to a specific radiobiological model and different strategies for acquiring the necessary parameters have been investigated. The basic approach, however, is independent of the precise form of the chosen model and could be used to assess the validity of a range of models in a clinical setting.
Of the two approaches discussed for deriving the radiosensitivity parameters, the optimization of the parameter set based on a minimal set of radiation response information is logistically the more attractive, for a number of reasons. First, it would require only two imaging sessions, and second only a single phase of treatment would be needed to derive the parameters, and this phase may form part of a conventionally prescribed treatment using a standard fractionation. However, in the case of the linear-quadratic model the optimization problem becomes effectively degenerate in the presence of image noise, and this technique is unlikely to prove practicable in a clinical setting. The analytical derivation based on multiple test phases may be logistically more difficult to implement as it requires numerous imaging sessions, relies on the careful coordination of treatment and imaging schedules, and necessitates deviations from conventional fractionations in order to produce the necessary information. However, this approach proves to be surprisingly robust to image noise, and the required variations in fractionation appear to be relatively modest. It also appears that adequate variations in overall treatment time between test phases may be achievable simply through judicious scheduling to make use of natural breaks in treatment ͑e.g., weekends͒. Overall, the analysis we have presented suggests that the application of this technique may be feasible using a clinically acceptable schedule of test treatments. In general, the number of imaging sessions required will depend on the complexity of the radiobiological model and will increase linearly with the number of independent parameters in the model. The basic methodology is sufficiently flexible to allow changes in the fundamental form of the model, or simply the extension of the model to include additional factors or phenomena, provided biological effect can be described by a linear function of the unknown parameters. The model could be extended such that hypoxic regions contain a mixture of active, quiescent, and necrotic cells, with quiescent cells becoming active with reoxygenation; the bystander effect could be modeled so that the TCP in one voxel depends on the dose in neighboring voxels; temporal variations in proliferation rate, if sufficiently well understood, could be incorporated into the model, as could the time delay between cell damage and cell death, and the subsequent clearance of dead cells. Conversely, if any of the parameters can be reliably determined prior to treatment ͑e.g., estimating proliferation rate using magnetic resonance spectroscopy, or a priori knowledge that the proliferation rate is negligible͒, fewer images will be needed to solve for the remaining free parameters.
Parametric sensitivity analysis and the application of the tuned radiobiological model to a number of modeled test cases showed that the dominant factor necessitating the redistribution of dose within a tumor was the reduction of radiosensitivity due to local hypoxia. The examples chosen indicate that where significant hypoxia exists, redistributing dose can lead to a substantial increase in TCP, and that even in the absence of hypoxia, if a relatively large volume of the target contains a low density of clonogens the redistribution of dose may allow a small but worthwhile increase in TCP, and may also benefit organs at risk peripheral to the target. This is in good agreement with other similar work. [19] [20] [21] 42 However, in contrast to previous studies, we not only suggest methods for accounting for spatial variations in oxygenation and clonogen density, we also present a means of determining the intrinsic radiosensitivity of an individual tumor. This in turn would allow a more accurate prediction of the biological effect of any given dose distribution or treatment schedule, and hence maximize the potential benefit of a personalized dose prescription. It should be noted that the optimized dose distributions presented here represent an ideal prescribed dose distribution over the tumor and take no account of organs at risk, or the clinical acceptability of the changes in voxel dose per fraction due to dose redistribution. In practice, a final treatment plan would need to be optimized considering normal tissue dose constraints and limitations in the physical delivery of treatment in addition to the ideal prescribed distribution, and in many cases the ideal distribution may not prove clinically deliverable. Our eventual aim is to combine the TCP model presented here with models predicting normal tissue complication probabilities ͑NTCP͒ within a treatment planning system combining the accurate calculation of dose deposition with detailed radiobiological modeling. This would allow the optimization of a deliverable plan balancing TCP and NTCP and accounting for the functional heterogeneity of both target and OARs. Normal tissue tolerance doses are likely to prove particularly restrictive in cases where regions of hypoxia and/or high clonogen density occur close to an OAR, and may significantly reduce the local target dose in these regions, and consequently the maximum achievable TCP. However, the magnitude of the potential increases in TCP shown for hypoxic tumors suggests that FIG. 7 . Initial parametric maps and final dose distributions for four tumor models. The parameters assigned to each model are given in Table II. even in cases where only a limited redistribution of dose was possible, substantial increases in TCP may be achievable within sensible clinical constraints.
Potentially the most serious limitation of our current model is the implicit assumption that cell death occurs effectively instantaneously following irradiation. This is clearly not the case, and there are two obvious approaches to solving this problem. The first would be to adapt the schedules to allow several cell cycles between each treatment phase and the subsequent imaging session, allowing the majority of cell damage to be fully expressed. This would be less than ideal for rapidly proliferating tumors as it would result in prolonging the overall treatment. The second alternative would be to incorporate the time dependence of the progression from cell damage to cell death into the radiobiological model, requiring a more thorough understanding of this process than is currently available in the literature. A recent study by Lim et al. 55 presents a model for cervical cancer regression during radiotherapy, accounting for cell clearance rate. However, the authors acknowledge that it is difficult to distinguish between differences in repopulation rate and cell clearance rate in such a model and have chosen to ignore the effects of repopulation, whilst we have included repopulation and ignored the cell clearance rate. Encouragingly, recent work by Yang et al. 56 suggests that early evaluation of the response of tumors to irradiation may be possible by developing markers to image early changes in cellular behavior, such as proliferation, which correlate well with eventual cell survival.
Another major challenge in the clinical implementation of this method arises from the fact that it relies on each tumor voxel representing the same group of cells throughout, both for treatment and for imaging sessions. Variations in patient setup, weight loss or gain, internal organ motion, and tumor shrinkage will all pose problems in this respect. Image guidance is therefore essential to enable the precise determination of the delivered dose distribution at each fraction, and elastic registration techniques may be required if the relative positions of tumor voxels change through the course of treatment.
The model we have presented is limited by the availability of suitable imaging, radiobiological assumptions, and clinical practicality, and the development and assessment of suitable parametric imaging techniques remains paramount. However, even given sizable uncertainties in parametric data we have demonstrated significant potential gains, showing how this kind of technique could unlock the true potential of IMRT and functional imaging. It should also be noted that it would not be necessary to use clinically derived radiobiological parameters immediately to prescribe nonuniform dose distributions: In the first instance the technique could be used to simply calculate radiosensitivity and use the calculated parameters to predict TCP for a conventional final phase of treatment. From Eq. ͑8͒ it is clear that the calculation of ␣, ␤, and ␥ does not depend on absolute clonogen densities, but only on the ratios of pre-and posttreatment clonogen numbers. In order to simply calculate the model parameters we do not therefore need to be able to absolutely quantify clonogenic cell density, we simply need images from which relative tumor burden can be derived. Using the method in this manner would provide a means of testing the predictions of a radiobiological model in a clinical setting prior to the application of the model for dose prescription.
V. CONCLUSION
We have considered the question of how emerging functional imaging techniques may be used to inform the planning of radiotherapy treatments and proposed a formalism for using functional imaging both to determine patientspecific radiobiological properties and to prescribe an optimal nonuniform dose distribution based on these parameters. The feasibility of this approach has been demonstrated by application to a specific radiobiological model. The development and validation of techniques for quantitative imaging of both tumor burden and hypoxia would pave the way for clinical trials to assess the validity of current models for predicting tumor response. This in turn would allow the technique to be used to prescribe optimal dose distributions for individual patients. Results show potential for significant improvements in tumor control over a range of realistic parameters and assumptions.
APPENDIX: CONSTRAINED MAXIMIZATION OF TCP
The Lagrange multiplier method can be used to maximize TCP as follows.
For fixed integral target dose E t ,
where m i is the mass of the i th voxel. Let
͑A2͒
For maximum total TCP, 
It can then be shown that 
